Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells.
Ngai H, Barragan GA, Tian G, Balzeau JC, Zhang C, Courtney AN, Guo L, Xu X, Wood MS, Drabek JM, Demberg T, Sands CM, Chauvin-Fleurence CN, Di Pierro EJ, Rosen JM, Metelitsa LS. Ngai H, et al. Among authors: metelitsa ls. Cancer Immunol Res. 2023 Feb 3;11(2):171-183. doi: 10.1158/2326-6066.CIR-22-0333. Cancer Immunol Res. 2023. PMID: 36484736 Free PMC article.
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15.
Tian G, Courtney AN, Yu H, Bhar S, Xu X, Barragán GA, Martinez Amador C, Ghatwai N, Wood MS, Schady D, Montalbano A, Reddy S, Roche AM, de la Cerda D, Parsons DW, Di Pierro EJ, Bushman FD, Heczey A, Metelitsa LS. Tian G, et al. Among authors: metelitsa ls. J Immunother Cancer. 2025 Jan 11;13(1):e010156. doi: 10.1136/jitc-2024-010156. J Immunother Cancer. 2025. PMID: 39800376 Free article.
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma.
Xu X, Huang W, Heczey A, Liu D, Guo L, Wood M, Jin J, Courtney AN, Liu B, Di Pierro EJ, Hicks J, Barragan GA, Ngai H, Chen Y, Savoldo B, Dotti G, Metelitsa LS. Xu X, et al. Among authors: metelitsa ls. Clin Cancer Res. 2019 Dec 1;25(23):7126-7138. doi: 10.1158/1078-0432.CCR-19-0421. Epub 2019 Sep 4. Clin Cancer Res. 2019. PMID: 31484667 Free PMC article.
Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
Batra SA, Rathi P, Guo L, Courtney AN, Fleurence J, Balzeau J, Shaik RS, Nguyen TP, Wu MF, Bulsara S, Mamonkin M, Metelitsa LS, Heczey A. Batra SA, et al. Among authors: metelitsa ls. Cancer Immunol Res. 2020 Mar;8(3):309-320. doi: 10.1158/2326-6066.CIR-19-0293. Epub 2020 Jan 17. Cancer Immunol Res. 2020. PMID: 31953246 Free PMC article.
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, Amador CM, Ghatwai N, Rathi P, Wood MS, Li Y, Zhang C, Demberg T, Di Pierro EJ, Sher AC, Zhang H, Mehta B, Thakkar SG, Grilley B, Wang T, Weiss BD, Montalbano A, Subramaniam M, Xu C, Sachar C, Wells DK, Dotti G, Metelitsa LS. Heczey A, et al. Among authors: metelitsa ls. Nat Med. 2023 Jun;29(6):1379-1388. doi: 10.1038/s41591-023-02363-y. Epub 2023 May 15. Nat Med. 2023. PMID: 37188782 Clinical Trial.
56 results